Last updated on October 2018

Study of Adjuvant ONO-4538 With Resected Gastric Cancer


Brief description of study

The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.

Clinical Study Identifier: NCT03006705

Contact Investigators or Research Sites near you

Start Over

Ono Pharmaceutical Co. Ltd Corporate ...

Hokkaido Clinical Site
Sapporo, Japan
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.